REGENXBIO Inc. (NASDAQ: RGNX) announced the pricing of an underwritten public offering of 10,003,889 shares of common stock at $9.00 per share and 1,111,111 pre-funded warrants at $8.9999 per warrant, according to a press release from the Rockville, Md.-based biotechnology company.

The gross proceeds from the offering are expected to be approximately $100.0 million, before underwriting discounts, commissions, and other offering expenses. The offering is expected to close on July 20, 2026, subject to customary closing conditions.

REGENXBIO has also granted underwriters a 30-day option to purchase up to an additional 1,667,250 shares of common stock at the public offering price, less underwriting discounts and commissions.

Morgan Stanley, J.P. Morgan, Leerink Partners, and Mizuho are acting as joint book-running managers for the offering.

The securities are being offered pursuant to a Registration Statement on Form S-3 filed with the Securities and Exchange Commission on November 26, 2025, and declared effective on December 12, 2025.